Cancer Genetics and Women's Health

Zawacki, Kristin L.; Phillips, Marcia

doi:10.1111/j.1552-6909.2002.tb00042.x

Cited by 3 publications

(3 citation statements)

References 35 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The International Society of Nurses in Genetics (ISONG) has identified the role of nurses in assessing risk factors, providing information or services and evaluating patients for referral (ISONG 1998), facilitating informed decision‐making (ISONG 2000), supporting access to genetic counselling for vulnerable populations (ISONG 2002), and supporting access to genomic health care (ISONG 2003). Genetic advances will have specific implications for a number of nursing professional groups, including oncology nurses (MacDonald 1997), gastroenterology nurses (Rieger & Tinley 2000), advanced practice nurses (Zawacki & Phillips 2002), perioperative nurses (Lea & Tinley 1998), paediatric nurses (Lessick & Anderson 2000) and midwives and other nursing professionals involved in prenatal and neonatal screening (Grant 2000, Lloyd‐Puryear & Forsman 2002, Burton & Shuttleworth 2003).…”

Section: Resultsmentioning

confidence: 99%

Genetics education in the nursing profession: literature review

Burke¹,

Kirk²

2006

Journal of Advanced Nursing

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Genetics education in the nursing profession: literature review

Burke¹,

Kirk²

2006

Journal of Advanced Nursing

View full text Add to dashboard Cite

show abstract

“…There is debate over the definition of a genetic test related to heritability, which is beyond the scope of this manuscript; however, brief insight is provided by using cancer as an example. Cancer is a genetic disease because all cancer is the result of changes in DNA or chromosome structure, leading to alterations in specific genes or gene expression 1 . However, not all cancers are heritable, and most genetic mutations that cause cancer occur sporadically in somatic cells (i.e., any cell other than the germ line cells).…”

Section: What Is a Genetic Test?mentioning

confidence: 99%

“…Cancer is a genetic disease because all cancer is the result of changes in DNA or chromosome structure, leading to alterations in specific genes or gene expression. 1 However, not all cancers are heritable, and most genetic mutations that cause cancer occur sporadically in somatic cells (i.e., any cell other than the germ line cells). Some individuals have specific genetic changes in their germ line cells that predispose them to cancer.…”

Section: What Is a Genetic Test?mentioning

confidence: 99%

A Primer on Genetic Testing

Constantin

Faucett

Lubin

2005

J Midwife Womens Health

View full text Add to dashboard Cite

Use of genetic tests in the clinical practice setting is a current reality, and an increasing number of patients are asking about and requesting genetic testing. The push to translate genetic research findings and technological innovations into clinical practice will continue as our understanding of the genetic basis of disease increases. Special consideration is required when ordering genetic tests, beyond that of other laboratory tests, and an understanding of the unique aspects involved will help optimize clinical outcomes. The purpose of this primer is to provide a basic understanding of genetic testing, discuss current issues related to the use of tests, and outline practical steps for critically using genetic tests in clinical practice.

show abstract

LINC01016 promotes the malignant phenotype of endometrial cancer cells by regulating the miR-302a-3p/miR-3130-3p/NFYA/SATB1 axis

Pan

Huo

et al. 2018

Cell Death Dis

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) have been implicated in tumorigenesis and cancer progression and are tightly associated with the phenotypes of numerous cancers. However, the functional roles underlying these effects are unknown. The expression levels of LINC01016, miR-302a-3p, miR-3130-3p, NFYA, and SATB1 were evaluated by quantitative real-time polymerase chain reaction (qRT-PCR) in 33 endometrial cancer tissues and 20 normal tissues. Bioinformatics analyses, luciferase reporter analyses, chromatin immunoprecipitation (ChIP) assays, and qRT-PCR assays were performed to verify potential binding sites. The qRT-PCR and western blot were used to identify the regulatory mechanisms of LINC01016 in cell biological behavior, which were also examined by cell counting kit -8 (CCK-8), 5-ethynyl-2′-deoxyuridine (EdU) assays, flow cytometry, wound healing assays, and transwell assays. LINC01016 was substantially upregulated in endometrial cancer tissues, and LINC01016 silencing abolished the malignant behavior of endometrial cancer cells. LINC01016 positively rescued the downstream gene nuclear factor YA (NFYA) by competitively “sponging” miR-302a-3p and miR-3130-3p. In turn, these two miRNAs could inhibit LINC01016 transcription, thus forming two reciprocal repression cycles, which influenced the biological behavior of endometrial cancer cells. MiR-302a-3p and miR-3130-3p could specifically bind with the 3′-UTR regions of NFYA, and NFYA could upregulate the expression of special AT-rich sequence-binding protein 1 (SATB1) as a transcriptional factor. This study was the first to show that the LINC01016–miR-302a-3p/miR-3130-3p/NFYA/SATB1 axis played a crucial role in the occurrence of endometrial cancer. These findings may provide relevant insights into the diagnosis and therapy of endometrial cancer.

show abstract

Cancer Genetics and Women's Health

Cited by 3 publications

References 35 publications

Genetics education in the nursing profession: literature review

Genetics education in the nursing profession: literature review

A Primer on Genetic Testing

LINC01016 promotes the malignant phenotype of endometrial cancer cells by regulating the miR-302a-3p/miR-3130-3p/NFYA/SATB1 axis

Contact Info

Product

Resources

About